Proton Radiation for Chordomas and Chondrosarcomas

This trial will be conducted in two phases: a feasibility then a phase II trial. Once
feasibility and safety are established in the first 12 pts. the phase II study will begin.
Proton therapy at standard doses is not known to improve clinical outcome but will likely
reduce fatigue and toxicity.

Inclusion Criteria:

- Histologically confirmed diagnosis of chordoma or chondrosarcoma.

- Patients must have no evidence of metastatic disease based on routine imaging (CT or
MRI of the chest/abdomen/pelvis, bone scan, etc.)

- Patients must have an ECOG score equal to or less than 2.

- Age ≥ 18 years.

- Patients must be able to provide informed consent.

- Adequate bone marrow function: WBC ≥ 4000/mm3, platelets ≥ 100, 000mm3

- Women of child-bearing potential as long as she agrees to use a recognized method of
birth control (e.g. oral contraceptive , IUD, condoms or other barrier methods etc.)
Hysterectomy or menopause must be clinically documented.

- Tumors arising in the skull and spine.

Exclusion Criteria:

- Prior or simultaneous malignancies within the past two years (other than cutaneous
squamous or basal cell carcinoma, melanoma in situ or thyroid carcinoma)

- Patients with the following histologies are excluded: melanoma , other soft tissue or
bony sarcomas, giant cell tumor aneurismal bone cyst or metastatic lesions from other
histologies.

- Pregnant women.

- Actively being treated on any other therapeutic research study.

- Tumors arising outside of the CNS.